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Abstract
Background Ulcerative colitis (UC) is a chronic autoim-
mune inflammation of the colon. The condition signifi-
cantly decreases quality of life and generates a substantial
economic burden for healthcare payers, patients and the
society in which they live. Some patients require chronic
pharmacotherapy, and access to novel biologic drugs might
be crucial for long-term remission. The analyses of cost-
effectiveness for biologic drugs are necessary to assess
their efficiency and provide the best available drugs to
patients.
Objective Our aim was to collect and assess the quality of
economic analyses carried out for biologic agents used in
the treatment of UC, as well as to summarize evidence on
the drivers of cost-effectiveness and evaluate the transfer-
ability and generalizability of conclusions.
Methods A systematic database review was conducted
using MEDLINE (via PubMed), EMBASE, Cost-Effec-
tiveness Analysis Registry and CRD0. Both authors inde-
pendently reviewed the identified articles to determine their
eligibility for final review. Hand searching of references in
collected papers was also performed to find any relevant
articles. The reporting quality of economic analyses
included was evaluated by two reviewers using the
International Society of Pharmacoeconomics and Out-
comes Research (ISPOR) Consolidated Health Economic
Evaluation Reporting Standards (CHEERS) statement
checklist. We reviewed the sensitivity analyses in cost-
effectiveness analyses to identify the variables that may
have changed the conclusions of the study. Key drivers of
cost-effectiveness were selected by identifying uncertain
parameters that caused the highest change of the results of
the analyses compared with base-case results.
Results Of the 576 identified records, 87 were excluded as
duplicates and 16 studies were included in the final review;
evaluations for Canada, the UK and Poland were mostly
performed. The majority of the evaluations revealed were
performed for infliximab (approximately 75% of total
volume); however, some assessments were also performed
for adalimumab (50%) and golimumab (31%). Only three
analyses were conducted for vedolizumab, whereas no
relevant studies were found for etrolizumab and tofacitinib.
The reporting quality of the included economic analyses
was assessed as high, with an average score of 21 points
per 24 maximum possible (range 14–23 points according to
the ISPOR CHEERS statement checklist). In the case of
most analyses, quality-adjusted life-years were used as a
clinical outcome, and endpoints such as remission,
response and mucosal healing were less common. The
higher clinical effectiveness (based on response rates) of
biological treatment over non-biological treatments was
presented in revealed analyses. The incremental cost-utility
ratios for biologics, compared with standard care, varied
significantly between the studies and ranged from
US$36,309 to US$456,979. The lowest value was obtained
for infliximab and the highest for the treatment scheme in-
cluding infliximab 5 mg/kg and infliximab 10 mg/
kg? adalimumab. The change of utility weights and clin-
ical parameters had the most significant influence on the
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results of the analysis; the variable related to surgery was
the least sensitive.
Conclusions Limited data on the cost-effectiveness of UC
therapy were identified. In the majority of studies, the lack
of cost-effectiveness was revealed for biologics, which was
associated with their high costs. Clinical outcomes are
transferable to other countries and could be generalized;
however, cost inputs are country-specific and therefore
limit the transferability and generalizability of conclusions.
The key drivers and variables that showed the greatest
effect on the analysis results were utility weights and
clinical parameters.
Key Points
The majority of the identified economic evaluations
related to the most commonly used agents:
infliximab, adalimumab and golimumab. Most
analyses were performed for Canada, the UK and
Poland.
Higher clinical effectiveness (reported as response
rates) of biologic drugs over reference therapies was
revealed and additional clinical effect of biologics in
terms of quality-adjusted life-years was presented in
economic analyses. The cost-effectiveness of
biological treatment, compared with standard care
alone, was reported in three analyses, and, in nine
studies, biologics were described as inefficient.
Infliximab was cost-effective when compared with
cyclosporine or surgical treatment.
Utility weights and clinical parameters are the main
key drivers of the cost-effectiveness of biologic
treatments in UC.
1 Introduction
Ulcerative colitis (UC) is an inflammatory bowel disease
characterized by the chronic inflammation of colonic
mucosa. Patients with UC typically present with bloody
diarrhoea, the passage of pus or mucus (or both), and
abdominal cramping during bowel movements [1]. The
clinical course is difficult to predict and changeable due to
alternating periods of remissions and exacerbations, which
may occur spontaneously or in response to external triggers
(e.g. treatment changes) [2, 3].
The annual incidence of UC is from 0 to 19.2 per
100,000 persons in North America, and from 0.6 to 24.3
per 100,000 persons in Europe. The prevalence ranges from
37.5 to 248.6 per 100,000 persons in North America, and
from 4.9 to 505 per 100,000 persons in Europe [4].
The main goal of UC pharmacotherapy is to effectively
obtain the remission of symptoms, and subsequently
maintain symptom-free periods. Patients affected with UC
often require expensive, lifelong treatment, and sometimes
surgery, both of which generate great direct costs to the
healthcare payer. Conventional therapy includes corticos-
teroids, 5-aminosalicylates (5-ASA; 5-aminosalicylic acid)
and thiopurines [3]. Biologics, which target a specific
inflammatory mediator, are used in patients with moderate-
to-severe chronic UC who are unresponsive or intolerant to
current therapy. The following biologics are currently
being assessed or are already used for UC therapy: tumour
necrosis factor inhibitors (infliximab, adalimumab, goli-
mumab), integrin antagonists (vedolizumab, etrolizumab)
and Janus kinase (JAK) inhibitors (tofacitinib) [5].
Clinical trials revealed that the biologics are effective in
UC therapy, but also generate a heavy burden on healthcare
service providers and payers [5, 6]. The increasing preva-
lence and high costs of UC pharmacotherapy and surgery
constitute a considerable challenge for healthcare systems
and generate a need for efficient and cost-effective man-
agement of this chronic long-term disease [7]. The cost-
effectiveness of different treatment strategies is required to
make objective and verifiable reimbursement decisions,
providing patients with the best treatment regimens
available.
Previous reviews on a similar topic did not provide a
comprehensive assessment of the quality of cost-effec-
tiveness analyses and the key drivers of cost-effectiveness
were not identified. The objective of our study was to
systematically review medical databases to collect relevant
publications on the cost-effectiveness of biologic treatment
in UC, and to perform a sophisticated and extensive review
of the methodologies used in the economic evaluations, as
well as assess the quality of the collected studies and
identify the key drivers of cost-effectiveness.
2 Materials and Methods
2.1 Systematic Literature Search
A systematic literature review was performed in July 2017
in order to obtain data on the efficiency of the biologic
treatments of UC. The following databases were searched:
MEDLINE (via PubMed), EMBASE, the Cost-Effective-
ness Analysis (CEA) Registry and Centre for Reviews and
Dissemination (CRD). The following terms were used to
define the population studied: ulcerative colitis, ulcerative
disease, colitis ulcerosa. We focused on the biologics that
are authorized for use in UC in Europe and/or in the US:
420 E. Stawowczyk, P. Kawalec
infliximab, adalimumab, golimumab, vedolizumab, etroli-
zumab, and tofacitinib. The following terms were used to
define the intervention: biologic, TNF, tumor necrosis
factor, tumour necrosis factor, infliximab, adalimumab,
golimumab, Remsima, Remicade, Inflectra, Humira, Sim-
poni, integrin antagonist, vedolizumab, Entyvio, JAK
inhibitor, Janus kinases, etrolizumab, tofacitinib, Xeljanz,
Jakvinus. The following terms were also used: economic
analysis, economic assessment, economic evaluation, cost-
effectiveness, cost efficacy, and cost-utility. A detailed
search strategy is available as electronic supplementary
material. The CEA Registry was searched using the term
‘ulcerative colitis’. In the CRD database, we omitted terms
connected with the type of analysis.
The population included was described by the Popula-
tion, Intervention, Comparator, Outcome (PICO) scheme:
P—patients with moderate-to-severe UC (studies con-
ducted in subpopulations were also included); I—biologic
therapy with infliximab, adalimumab, golimumab, vedoli-
zumab, etrolizumab or tofacitinib; C—not applicable, all
other UC treatments were included; O—cost-effectiveness
or cost-utility analyses.
The systematic review was independently carried out by
two researchers, based on the same search strategy. The
results for those searches were then compared; for dis-
agreements, collaborative reassessment of the review
results was performed to reach a final consensus.
2.2 Study Selection
Papers written in English were included. Neither country
nor date filters were used. Original studies including pri-
mary data on the cost-effectiveness of biologics in UC, as
well as reviews that led to previously undiscovered effi-
ciency assessments, were included. Conference abstracts
and posters were excluded as they did not provide the
details valid for our review. The following exclusion cri-
teria were implemented: a different intervention studied
(i.e. pharmacotherapy other than biologics, surgery), dif-
ferent population (Crohn disease, other inflammatory bowel
diseases) and different endpoints (i.e. cost assessments,
clinical analyses, budget impact analyses). In this review,
we included articles that fulfilled the inclusion criteria,
defined within the PICO scheme, and which did not meet
the exclusion criteria. During the selection of records, we
used the Preferred Reporting Items for Systematic Reviews
and the Meta-Analyses (PRISMA) statement.
2.3 Extraction and Presentation of Data
Data were extracted from the articles eligible. We used the
Cochrane Handbook for Systematic Reviews of Intervention
[8] to determine the terms collected: the first author’s name,
population, interventions, comparators, year of study, study
design (assumptions and methods of the main analysis, i.e.
the type of economic analysis, outcomes, perspective,
country, time horizon, discount rates, cost reference date,
currency, type of sensitivity analysis), results (total and
incremental costs, total and incremental outcomes, incre-
mental cost-effectiveness ratio/incremental cost-utility ratio
[ICER/ICUR] value, conclusions on cost-effectiveness,
results of sensitivity analysis). Two contributors discussed
the discrepancies until a consensus was reached.
2.4 Quality Assessment
The reporting quality of the identified studies was assessed
using the International Society of Pharmacoeconomics and
Outcomes Research (ISPOR) Consolidated Health Eco-
nomic Evaluation Reporting Standards (CHEERS) state-
ment checklist. It does not evaluate the quality of conduct,
however its objective is to ensure that the analyses are fully
reported. This instrument consists of a 24-item checklist [9]
verifying the presence of specific issues (e.g. perspective,
comparators, time horizon) in the considered papers.
Two authors reviewed the studies and scored each
question 0 (this particular aspect is not present) or 1 (this
particular aspect is present). Any discrepancies were
resolved by consensus.
2.5 Synthesis of Data
The identified studies were grouped depending on the type
of biologics they investigated: infliximab, adalimumab,
golimumab, vedolizumab, and other biologics. Cost-ef-
fectiveness was assessed based on conclusions presented
by authors of the eligible studies.
3 Results
3.1 Study Selection
The systematic search identified 576 references. After
removing duplicates, 489 remaining records were submit-
ted for further selection based on the review of their titles
and abstracts, when necessary. In the next step, we exclu-
ded 457 records for the following reasons: a different type
of analysis (e.g. cost comparisons, budget impact analyses,
clinical effectiveness analyses), secondary data (reviews),
different intervention, different population (e.g. inflam-
matory bowel diseases in general, Crohn disease). Of the
32 records selected by full-text review, 16 were excluded
due to secondary data (systematic reviews), ineligible
publication type (conference abstracts), and different pop-
ulation or endpoints. The remaining 16 records were
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included in the review (Fig. 1). In our review, we found
four reports for Canada, three for Poland, and two for
England and Wales, as well as four for the UK. Additional
evaluations were performed for The Netherlands, Iran and
the US.
3.1.1 Infliximab
Most of the identified studies related to infliximab (75%;
n = 12), two of which were cost-effectiveness analyses
with response and/or remission and/or mucosal healing as
the outcomes [10, 11], and ten were cost-utility evaluations
with quality-adjusted life-year (QALY) as an outcome.
Four analyses used decision trees as an analytic technique
[11–14], whereas the Markov modelling was used in the
remaining evaluations. In the study by Wilson et al. [14],
both the above modelling techniques were used (Table 1).
Two analyses (Punekar and Hawkins [13] and Tsai et al.
[15]) showed that infliximab is a cost-effective treatment
option compared with standard care alone, whereas six
other analyses revealed opposite conclusions [16–21],
namely, the ICER/ICUR value exceeded the threshold
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Fig. 1 PRISMA flow diagram showing the record selection process. Reason A—different intervention; Reason B—different type of study/
endpoint; Reason C—different population. PRISMA Preferred Reporting Items for Systematic Reviews and Meta-Analyses
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Table 1 Characteristics of the included studies
Study, year Population Treatment Study characteristics
Beilman
et al., 2016
[23]
Moderate-to-severe active UC,
corticosteroid-dependent and/or did not
respond to thiopurine therapy
Adalimumab 160/80/
40 mg, standard care
Type: Cost-utility analysis
Model: Markov
Horizon: 10 years
Outcomes: QALY
Discounting (costs/effects): 5%/5%
Country: Canada
Perspective: NA
Reference year: NA
Sponsor: Supported by the Centre of Excellence for
Gastrointestinal Inflammation and Immunity
Research
Chaudhary
and Fan,
2013 [12]
Sever UC adult patients hospitalized
with an acute exacerbation of the
disease
Infliximab 5 mg/kg,
cyclosporine 2 mg/kg,
surgical intervention
Type: Cost-utility analysis
Model: Decision tree
Horizon: 1 year
Outcomes: QALY
Discounting (costs/effects): 4%/1.5%
Country: The Netherlands
Perspective: National payer
Reference year: 2010
Sponsor: Merck & Co., Inc.
Moradi et al.,
2016 [19]
Moderate-to-severe UC Infliximab 5 mg/kg,
conventional treatments
Type: Cost-utility analysis
Model: Markov
Horizon: 5 years
Outcomes: QALY
Discounting (costs/effects): 5%/NA
Country: Iran
Perspective: Public payer
Reference year: 2014
Sponsor: No
Punekar and
Hawkins,
2010 [13]
Moderate-to-severe UC patients
hospitalized with an acute exacerbation
of the disease
Infliximab 5 mg/kg,
cyclosporine 4 mg/kg,
surgery, standard care
Type: Cost-utility analysis
Model: Decision tree
Horizon: 1 year
Outcomes: QALY
Discounting (costs/effects): 3.5%/3.5%
Country: England, Wales
Perspective: Public payer
Reference year: 2006–2007
Sponsor: Schering-Plough Ltd
Stawowczyk
et al., 2016
[22]
Moderate-to-severe UC Adalimumab 160/80/
40 mg, standard care
Type: Cost-utility analysis
Model: Markov
Horizon: 30 years
Outcomes: QALY
Discounting (costs/effects): 5%/3.5%
Country: Poland
Perspective: Public payer, social
Reference year: 2015
Sponsor: No
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Table 1 continued
Study, year Population Treatment Study characteristics
Stawowczyk
et al., 2016
[24]
Moderate-to-severe UC Golimumab 200/100/
50 mg, standard care
Type: Cost-utility analysis
Model: Markov
Horizon: 30 years
Outcomes: QALY
Discounting (costs/effects): 5%/3.5%
Country: Poland
Perspective: Public payer, social
Reference year: 2015
Sponsor: No
Stawowczyk
et al., 2016
[21]
Moderate-to-severe UC Infliximab 5 mg/kg,
standard care
Type: Cost-utility analysis
Model: Markov
Horizon: 30 years
Outcomes: QALY
Discounting (costs/effects): 5%/3.5%
Country: Poland
Perspective: Public payer
Reference year: 2015
Sponsor: No
Tappenden
et al., 2016
[17]
Moderate-to-severe UC in patients for
whom at least one prior therapy has
failed
Infliximab 5 mg/kg,
adalimumab 160/80/
40 mg, golimumab 200 g/
100/100 mg (50 mg),
conventional non-biologic
therapy, elective surgery
Type: Cost-utility analysis
Model: Markov
Horizon: 60 years
Outcomes: QALY
Discounting (costs/effects): 3.5%/3.5%
Country: UK
Perspective: Public payer, Personal Social Services
Reference year: 2013/2014
Sponsor: National Institute for Health Research Health
Technology Assessment Programme
Toor et al.,
2015 [10]
Moderate-to-severe UC Infliximab 5 mg/kg,
adalimumab 40 mg,
golimumab 50/100 mg,
conventional therapy
Type: Cost-effectiveness analysis
Model: Markov
Horizon: 1 year
Outcomes: Remission, response
Discounting (costs/effects): –
Country: Canada
Perspective: Public payer
Reference year: 2013
Sponsor: Janssen Inc. Canada
Tsai et al.,
2008 [15]
Moderate-to-severe UC Infliximab 5 mg/kg,
standard care
Type: Cost-utility analysis
Model: Markov
Horizon: 10 years
Outcomes: QALY
Discounting (costs/effects): 3.5%/3.5%
Country: England, Wales
Perspective: Public payer
Reference year: 2006/2007
Sponsor: Schering-Plough Ltd
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Table 1 continued
Study, year Population Treatment Study characteristics
Ung et al.,
2014 [20]
Moderate-to-severe UC Infliximab 5 mg/kg,
standard care
Type: Cost-utility analysis
Model: Markov
Horizon: 10 years
Outcomes: QALY
Discounting (costs/effects): 5%/5%
Country: Canada
Perspective: Health system
Reference year: 2013
Sponsor: Supported by the Centre of Excellence for
Gastrointestinal Inflammation and Immunity
Research and the Alberta Innovates
Wilson et al.,
2017 [14]
Moderate-to-severe UC Vedolizumab 300 mg,
infliximab 5 mg/kg,
adalimumab 160/80/
40 mg, golimumab
100/50/50 mg,
conventional therapy
Type: Cost-utility analysis
Model: Decision tree/Markov
Horizon: Lifetime
Outcomes: QALY
Discounting (costs/effects): 3.5%/3.5%
Country: UK
Perspective: Public payer, Personal Social Services
Reference year: 2012/2013
Sponsor: Takeda Pharmaceuticals, AG
Xie et al.,
2009 [18]
Moderate-to-severe refractory UC Infliximab 5/10 mg,
adalimumab 160/80/
40 mg, usual care
Type: Cost-utility analysis
Model: Markov
Horizon: 5 years
Outcomes: QALY
Discounting (costs/effects): 5%/5%
Country: Canada
Perspective: Public payer
Reference year: 2008
Sponsor: No
Yokomizo
et al., 2016
[11]
Moderate-to-severe UC Infliximab 5/10 mg,
adalimumab 160/80/
40 mg, vedolizumab 300
mg
Type: Cost-effectiveness analysis
Model: Decision tree
Horizon: 1 year
Outcomes: Remission, mucosal healing
Discounting (costs/effects): –
Country: US
Perspective: Third party’s
Reference year: 2014
Sponsor: National Institute of Diabetes and Digestive
and Kidney Diseases
Archer et al.,
2016 [16]
Moderate-to-severe UC, after the failure
of conventional treatment
Infliximab 5 mg/kg,
adalimumab 160/80/
40 mg, golimumab
200/100/100 mg (50 mg),
conventional therapy,
colectomy
Type: Cost-utility analysis
Model: Markov
Horizon: Lifetime
Outcomes: QALY
Discounting (costs/effects): 3.5%/3.5%
Country: UK
Perspective: Public payer, Personal Social Services
Reference year: 2013
Sponsor: National Institute for Health Research
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value in a particular country. In the study by Chaudhary
and Fan [12], infliximab was shown to be cost-effective
when compared with cyclosporine therapy and surgical
intervention. Toor et al. [10] concluded that infliximab had
the highest clinical efficacy (presented as response and
remission), but also generated high costs compared with
adalimumab and golimumab. In comparison with adali-
mumab and vedolizumab, infliximab turned out to be the
most cost-effective treatment option when remission and
mucosal healing were taken into account [11]. In the study
by Archer et al. [16], infliximab was expected to be dom-
inated by adalimumab (Table 2).
3.1.2 Adalimumab
Adalimumab was assessed in eight studies, six of which
were cost-utility analyses displaying QALY as an outcome
[14, 16, 17, 18, 22, 23]. The Markov modelling was used in
seven studies, decision trees in two studies [11, 14], and, in
the case of Wilson et al. [14], both analytic techniques
(Markov modelling and the decision tree) were used
(Table 1). Four studies showed that adalimumab is not a
cost-effective treatment option when compared with stan-
dard care alone [16–18, 22], and only one study reported the
opposite conclusion [23]. Toor et al. [10] concluded that
adalimumab produced higher cost per remission and cost
per response, when compared with standard care, than other
biologics, i.e. infliximab and golimumab. In the study by
Yokomizo et al. [11], adalimumab was dominated (proving
less effective and more costly) by infliximab, when mucosal
healing was included as an outcome (Table 2).
3.1.3 Golimumab
Golimumab was included as a treatment option in UC in
five studies, four of which were cost-utility analyses
[14, 16, 17, 24], and one included remission and response
as the outcomes [10]. All the studies used the Markov
modelling and one study additionally used a decision tree
[14] (Table 1). Stawowczyk et al. [24], Tappenden et al.
[17] and Archer et al. [16] concluded that golimumab is not
a cost-effective treatment option when compared with
standard care alone. In the study by Toor et al. [10],
golimumab had the lowest cost of 1 additional year of
remission and response compared with standard care,
among other biologics included, i.e. infliximab and adali-
mumab. Wilson et al. [14] showed that golimumab was
dominated by vedolizumab (Table 2).
3.1.4 Vedolizumab
Only three studies assessed the cost-effectiveness of vedoli-
zumab in the treatment of UC; one used a decision tree [11]
and two used both the decision tree and Markov modelling
[14, 25]. Wilson et al. [14] compared vedolizumab with other
biologics used in UC, i.e. infliximab, adalimumab and goli-
mumab, and concluded that it is a cost-effective treatment
option (Table 1). Vedolizumab generated the highest out-
comes (QALYs) and was cheaper than infliximab and goli-
mumab (therefore it dominated both comparators). Only
adalimumab proved to be cheaper than vedolizumab, but also
less effective—the ICER for vedolizumab compared with
adalimumab did not exceed the threshold value. Yokomizo
et al. [11] included mucosal healing as an outcome and
showed that vedolizumab was dominated by infliximab. Essat
et al. [25] described the results of Evidence Review Group
(ERG) assessment of vedolizumab. Based on the ERG’s own
calculations, it was shown that vedolizumab is expected to be
dominated by surgery (Table 2).
3.2 Quality Assessment
The results of quality assessment with the ISPOR CHEERS
statement checklist are shown in Table 3. The study by
Table 1 continued
Study, year Population Treatment Study characteristics
Essat et al.,
2016 [25]a
Moderate-to-severe UC Vedolizumab, conventional
therapy, surgery,
infliximab, adalimumab,
golimumab
Type: Cost-utility analysis
Model: Markov, decision-tree
Horizon: Lifetime
Outcomes: QALY
Discounting (costs/effects): NA
Country: UK
Perspective: Public payer
Reference year: NA
Sponsor: Evidence Review Group
UC ulcerative colitis, QALY quality-adjusted life-years, NA not available, ERG Evidence Review Group
aMethods and results of the ERG’s own calculations were included
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Table 2 Results of the included studies
Study, year Total costs Total outcomes ICER Authors’ conclusions
Beilman et al.,
2016 [23]
SC = US$97,000
ADA = US$107,000
SC = 3.154
ADA = 3.321
Per QALYG:
ADA vs. SC = US$59,000
ADA is cost-effective
compared with SC
Chaudhary and
Fan, 2013 [12]
IFX = €17,062
CSP = €14,784
S = €13,979
IFX = 0.80
CSP = 0.70
S = 0.58
Per QALYG:
IFX vs. CSP = €24,277
IFX vs. S = €14,639
IFX is cost-effective compared
with CSP and S
Moradi et al.,
2016 [19]
IFX = US$77,138
SC = US$985
IFX = 3.56
SC = 3.24
Per QALYG:
IFX vs. SC = US$240,903
IFX is not cost-effective
compared with SC
Punekar and
Hawkins, 2010
[13]
S = 17,067
CSP = 18,122
SC = 18,524
IFX = 19,847
S = 0.58
CSP = 0.70
SC = 0.68
IFX = 0.80
Per QALYG:
IFX vs. CSP = 19,545
IFX is cost-effective compared
with CSP, S, SC
Stawowczyk
et al., 2016 [22]
Public payer:
ADA = €20,598
SC = €9950
Social:
ADA = €93,765
SC = €83,770
ADA = 15.204
SC = 15.064
Per QALYG:
Public payer:
ADA vs. SC = €76,120
Social:
ADA vs. SC = €71,457
ADA is not cost-effective
compared with SC
Stawowczyk
et al., 2016 [24]
Public payer:
GOL = PLN93,321
SC = PLN45,502
Social:
GOL = PLN302,848
SC = PLN257,092
GOL = 19.241
SC = 19.118
Per QALYG:
Public payer:
GOL vs. SC = 391,252 PLN
Social:
GOL vs. SC = 374,377 PLN
GOL is not cost-effective
compared with SC
Stawowczyk
et al., 2016 [21]
IFX = PLN99,522
SC = PLN29,642
IFX = 14.296
SC = 14.123
Per QALYG:
IFX vs. SC = PLN402,420
IFX is not cost-effective
compared with SC
Tappenden et al.,
2016 [17]
S = 56,268
ADA = 91,222
IFX = 96,595
GOL = 90,087
SC = 73,620
S = 14.71
ADA = 10.82
IFX = 10.81
GOL = 10.63
SC = 10.47
Per QALYG:
S vs. ADA/IFX/GOL/SC–S dominated all
therapies
ADA vs. SC = 50,278
IFX vs. SC = 67,574a
GOL vs. SC = 102,919a
Colectomy dominated all
medical treatment.
ADA, IFXa, GOLa are not cost-
effective compared with SC
Toor et al., 2015
[10]
NA NA Per remission:
GOL 50 vs. SC = CAN$1048
GOL 100 vs. SC = CAN$935
IFX vs. SC = CAN$1975
ADA vs. SC = CAN$7430
IFX vs. GOL 100 = CAN$14,659
ADA vs. GOL 100 =- CAN$3324
Per response:
GOL 50 vs. SC = CAN$770
GOL 100 vs. SC = CAN$701
IFX vs. SC = CAN$1311
ADA vs. SC = CAN$2361
IFX vs. GOL 100 = CAN$4753
ADA vs. GOL 100 =- CAN$4019
GOL 100 and GOL 50 have the
lowest cost of additional
1 year of remission and
response; IFX has the highest
efficacy, but also high costs,
ADA produced the highest
cost/remission and response
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Essat et al. [25] was not assessed as it presents the results
of a Health Technology Assessment (HTA) rather than
typical economic analysis.
The identified economic analyses obtained a rather high
average result of the ISPOR CHEERS statement checklist,
equalling 21 points, with a minimum and maximum value
of 14 and 23, respectively. Only one study obtained the
minimum value [19], whereas the maximum value was
reached by three studies [14, 22, 24]. The most common
value was the average value, i.e. 21 points (see electronic
supplementary material).
All the included studies had adequate titles, which
identified the study as an economic evaluation (the most
common phrases were cost-effectiveness, cost-utility,
economic evaluation) and described the compared inter-
ventions. Studies failed to report relevant aspects on the
system in which the decision needed to be made—adequate
information was presented in only six studies (40%)
Table 2 continued
Study, year Total costs Total outcomes ICER Authors’ conclusions
Tsai et al., 2008
[15]
Responders only:
IFX = 66,460
SC = 45,798
Remission only:
IFX = 53,874
SC = 46,259
Responders
only:
IFX = 4.591
SC = 3.838
Remission only:
IFX = 4.154
SC = 3.767
Per QALYG:
Responders only:
IFX vs. SC = 27,424
Remission only:
IFX vs. SC = 19,696
IFX is cost-effective compared
with SC
Ung et al., 2014b
[20]
SC = US$86,000
IFX = US$98,000
SC = 3.204
IFX = 3.284
Per QALYG: IFX vs. SC = US$152,000 IFX is not cost-effective
compared with SC
Wilson et al.,
2017 [14]
VED = 199,431
IFX = 206,066
ADA = 194,765
GOL = 200,018
VED = 14.077
IFX = 13.788
ADA = 13.872
GOL = 13.809
Per QALYG:
VED vs. IFX—VED dominated IFX
VED vs. ADA = 22,775
VED vs. GOL—VED dominated GOL
VED is cost-effective
compared with IFX, ADA,
GOL
Xie et al., 2009
[18]
SC = CAN$24,268
IFX
ADA = CAN$82,756
IFX 5 IFX 10
ADA = CAN$101,272
SC = 2.015
IFX
ADA = 2.178
IFX 5 IFX 10
ADA = 2.149
Per QALYG:
IFX ADA vs. SC = CAN$358,088
IFX 5 IFX 10 ADA vs.
SC = CAN$575,540
Anti-TNFa therapies are not
cost-effective compared with
SC
Yokomizo et al.,
2016 [11]
IFX 5 = US$99,171
IFX 10 = US$123,653
ADA = US$316,378
VED = US$301,969
NA Per mucosal healing:
IFX 5 vs. IFX 10 = US$1,243,310
IFX 5 vs. ADA—IFX dominated ADA
IFX 5 vs. VED—IFX dominated VED
IFX is the most cost-effective
treatment option
Archer et al.,
2016 [16]
S = 56,267.73
ADA = 91,221.71
IFX = 96,594.62
GOL = 90,086.69
SC = 73,619.77
S = 14.71
ADA = 10.82
IFX = 10.81
GOL = 10.63
SC = 10.47
IFX vs. ADA—ADA dominated IFX
ADA vs. SC = 50,278
IFX vs. SC = 67,573a
GOL vs. SC = 102,918a
Surgery dominated all other
options. ADA dominated IFX
Essat et al., 2016
[25]c
NA NA Surgery is an option: VED vs. S—S
dominated VED
Surgery is not an option, mixed ITT
population: VED vs. SC = 53,084
Surgery is not an option, anti-TNFa failure
population: VED vs. SC = 48,205
When surgery is an option it
dominated VED. When
surgery is not an option, VED
was not cost-effective
compared with SC
CAN$1 = US$0.794; €1 = US$1.184; 1 = US$1.324; 1 PLN = US$0.278
IFX infliximab, ADA adalimumab, GOL golimumab, GOL 50 golimumab 50 mg, GOL 100 golimumab 100 mg, VED vedolizumab, SC standard/
usual care/conventional treatment, S surgery, CSP cyclosporine, QALYG quality-adjusted life-years gained, ICER incremental cost-effectiveness
ratio, NA not available, TNF tumor necrosis factor
aOur own calculations based on available data
bResults based on data from clinical studies
cResults of the ERG’s own calculations were included
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Table 3 The results of quality assessment of included studies with ISPOR CHEERS statement checklist
Section/item Item
no.
Recommendation Number of studies
in line with
recommendation
Percentage of studies
in line with
recommendation
Title and abstract
Title 1 Identify the study as an economic evaluation, or use more
specific terms such as ‘‘cost-effectiveness analysis’’ and
describe the interventions compared
15 100.0
Abstract 2 Provide a structured summary of objectives, perspective,
setting, methods (including study design and inputs),
results (including base-case and uncertainty analyses),
and conclusions
15 100.0
Introduction
Background and objectives 3 Provide an explicit statement of the broader context for the
study. Present the study question and its relevance for
health policy or practice decisions
15 100.0
Methods
Target population and
subgroups
4 Describe characteristics of the base-case population and
subgroups analyzed including why they were chosen
15 100.0
Setting and location 5 State relevant aspects of the system(s) in which the
decision(s) need(s) to be made
6 40.0
Study perspective 6 Describe the perspective of the study and relate this to the
costs being evaluated
14 93.3
Comparators 7 Describe the interventions or strategies being compared
and state why they were chosen
15 100.0
Time horizon 8 State the time horizon(s) over which costs and
consequences are being evaluated and say why
appropriate
15 100.0
Discount rate 9 Report the choice of discount rate(s) used for costs and
outcomes and say why appropriate
13 86.7
Choice of health outcomes 10 Describe what outcomes were used as the measure(s) of
benefit in the evaluation and their relevance for the type
of analysis performed
15 100.0
Measurement of
effectiveness
11a Single study–based estimates: Describe fully the design
features of the single effectiveness study and why the
single study was a sufficient source of clinical
effectiveness data
14 93.3
11b Synthesis-based estimates: Describe fully the methods used
for the identification of included studies and synthesis of
clinical effectiveness data
Measurement and
valuation of preference-
based outcomes
12 If applicable, describe the population and methods used to
elicit preferences for outcomes
13 86.7
Estimating resources and
costs
13a Single study–based economic evaluation: Describe
approaches used to estimate resource use associated with
the alternative interventions. Describe primary or
secondary research methods for valuing each resource
item in terms of its unit cost. Describe any adjustments
made to approximate to opportunity costs
15 100.0
13b Model-based economic evaluation: Describe approaches
and data sources used to estimate resource use associated
with model health states. Describe primary or secondary
research methods for valuing each resource item in terms
of its unit cost. Describe any adjustments made to
approximate to opportunity costs
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Table 3 continued
Section/item Item
no.
Recommendation Number of studies
in line with
recommendation
Percentage of studies
in line with
recommendation
Currency, price date, and
conversion
14 Report the dates of the estimated resource quantities and
unit costs. Describe methods for adjusting estimated unit
costs to the year of reported costs if necessary. Describe
methods for converting costs into a common currency
base and the exchange rate
13 86.7
Choice of model 15 Describe and give reasons for the specific type of decision-
analytic model used. Providing a figure to show model
structure is strongly recommended
14 93.3
Assumptions 16 Describe all structural or other assumptions underpinning
the decision-analytic model
13 86.7
Analytic methods 17 Describe all analytic methods supporting the evaluation.
This could include methods for dealing with skewed,
missing, or censored data; extrapolation methods;
methods for pooling data; approaches to validate or make
adjustments (e.g., half-cycle corrections) to a model; and
methods for handling population heterogeneity and
uncertainty
12 80.0
Results
Study parameters 18 Report the values, ranges, references, and if used,
probability distributions for all parameters. Report
reasons or sources for distributions used to represent
uncertainty where appropriate. Providing a table to show
the input values is strongly recommended
14 93.3
Incremental costs and
outcomes
19 For each intervention, report mean values for the main
categories of estimated costs and outcomes of interest, as
well as mean differences between the comparator groups.
If applicable, report incremental cost-effectiveness ratios
15 100.0
Characterizing uncertainty 20a Single study–based economic evaluation: Describe the
effects of sampling uncertainty for estimated incremental
cost, incremental effectiveness, and incremental cost-
effectiveness, together with the impact of methodological
assumptions (such as discount rate, study perspective)
20b Model-based economic evaluation: Describe the effects on
the results of uncertainty for all input parameters, and
uncertainty related to the structure of the model and
assumptions
14 93.3
Characterizing
heterogeneity
21 If applicable, report differences in costs, outcomes, or cost-
effectiveness that can be explained by variations between
subgroups of patients with different baseline
characteristics or other observed variability in effects that
are not reducible by more information
0 0.0
Discussion
Study findings, limitations,
generalizability, and
current knowledge
22 Summarize key study findings and describe how they
support the conclusions reached. Discuss limitations and
the generalizability of the findings and how the findings
fit with current knowledge
13 86.7
Other
Source of funding 23 Describe how the study was funded and the role of the
funder in the identification, design, conduct, and
reporting of the analysis. Describe other nonmonetary
sources of support
13 86.7
Conflicts of interest 24 Describe any potential for conflict of interest among study
contributors in accordance with journal policy. In the
absence of a journal policy, we recommend authors
comply with International Committee of Medical Journal
Editors’ recommendations
12 80.0
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[14, 16, 18, 21, 22, 24]. The healthcare system and reim-
bursement status of the drugs analysed in the particular
countries were rarely described. Study perspective was
rather properly described, only in one study was the
information missing [23]. In a majority of revealed anal-
yses [2, 12–19, 21, 22] a public payer perspective was
applied, and in the case of two evaluations [22, 24] a social
point of view was employed. One study [11] did not report
information on discount rates for costs and outcomes, but
the time horizon of this study was short (1 year) and dis-
counting was not needed. In another study [19], there was
no information regarding the discount rate for outcomes,
and only the rate for costs was reported. Preferences for
outcomes (utility weights) were included and properly
described in 13 studies (87%), whereas in the studies by
Toor et al. [10] and Yokomizo et al. [11] they were not
included because they employed a different type of anal-
ysis (cost-effectiveness, with remission and response as
outcomes). In some studies, information on the currency
and/or exchange rates was missing. Beilman et al. [23] did
not describe the year of reported costs, and Xie et al. [18]
presented 2008 costs in Canadian dollars but did not pre-
sent the exchange rate.
Only one study [10] did not reveal the values for main
study parameters; the authors presented only the cost per
remission and cost per response for biologics versus con-
ventional therapy and other biologics. The heterogeneity
was not assessed in any of the identified studies as no study
included subgroups.
3.3 Drivers of Cost-Effectiveness
3.3.1 Uncertainty Within the Study
In 14 studies (88%), sensitivity analyses were carried out,
and only in the study by Moradi et al. [19] were the
effects of sampling uncertainty for estimated results not
described as the authors failed to undertake the proba-
bilistic sensitivity analysis. In the study by Essat et al.
[25], where the results of HTA were presented, no
information on sensitivity analysis was available. Both
deterministic and probabilistic sensitivity analyses were
performed, and one-way sensitivity analysis was the most
often used type of deterministic sensitivity analyses. The
most common sensitive variables included in the analyses
were the parameters of efficacy (remission/response rates,
transition probabilities), utility weights, discount rates,
cost parameters, and patients’ characteristics (weight).
The majority of studies revealed that the change of utility
weights [12, 13, 16–18, 20–24] and clinical parameters,
i.e. remission/response rates, transition probabilities,
[13, 14, 17, 18, 21, 22, 24] had the highest influence on
analysis results (ICER/ICUR values). The change of
patients’ characteristics. i.e. body weight, [12, 13] also
had a significant influence on the results in some cases.
The costs were less often included in the sensitivity
analysis; however, they had a significant influence on the
results in a few cases, i.e. the cost of response to adali-
mumab treatment [23], infliximab cost [20], health-state
costs [14], and drug costs [11]. In two studies, the change
of the duration of treatment had a great influence on the
results of the analysis [10, 24]. The variable related to
surgery, i.e. the probability of surgical complications, was
the least sensitive [20, 21, 23, 24].
3.3.2 Uncertainty Between Studies
The results of some studies were also compared to
estimate the impact of model assumptions on the results
of the analysis. We chose analyses with the same out-
comes (i.e. QALY), the same comparator (i.e. standard
care) and the same intervention (i.e. infliximab, as the
highest number of studies related to this biologic).
Seven studies met the above criteria [15–21], but two
studies had to be subsequently excluded as one included
different treatment strategies (infliximab 5 mg/kg ? in-
fliximab 10 mg/kg? adalimumab, and inflix-
imab? adalimumab [18]), and one provided results
separately for responders and patients in remission [15].
The range of the ICUR value in the remaining studies
ranged from US$89,468 [16, 17] to US$240,903 [19];
however, the conclusions relating to cost-effectiveness
were the same: infliximab was not a cost-effective
option in the treatment of UC compared with standard
care alone. All analyses used the Markov modelling, but
the time horizon differed significantly from 5 years [19]
to lifetime [16], and the lowest and highest ICUR values
were obtained for analyses with the longest and shortest
time horizon, respectively. The other model assumptions
were similar—discount rates: 5% in the majority of
cases, or 3.5% in the studies by Tappenden et al. [17],
Archer et al. [16] and Stawowczyk et al. [21] (only for
effects); study perspective: public payer/health system;
reference year: 2013–2015; utility weights: based on the
studies by Arseneau et al. [26] (all studies) and Woehl
et al. [27] (studies [16, 17, 21]).
3.4 Model Structure
To compare the structures of the models, we first chose
analyses that used the Markov modelling as this was the
methodology most often performed; we identified 12 such
analyses [14–25], but in study by Essat et al. [25] the model
structure was not presented in a form of diagram and no
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detailed information was provided. That was the reason
why this study was excluded.
Beilman et al. [23] and Ung et al. [20] compared two
scenarios—when adalimumab is available and when it is not
available. Several health states were identified: unwell
during treatment, response (to pharmacotherapy or surgery),
complications (after pharmacotherapy or surgery) and death.
Chronic pouchitis was analysed regardless of complications
after surgery and was considered as a separate state.
The structure of the model presented by Moradi et al.
[19] was less sophisticated and included only three states,
i.e. remission, response and surgery.
All three models used in the studies by Stawowczyk
et al. [21, 22, 24] were similar and included the following
states: remission (after pharmacotherapy or surgery),
response, active disease, surgery, and complications after
surgery. The model for infliximab [21] additionally inclu-
ded the second-line treatment with adalimumab (after
failure of infliximab treatment).
Similar states and model structures were included in the
study by Tsai et al. [15], Archer et al. [16] and Tappenden
et al. [17]; however, only first-line biologic treatment was
included. Tsai et al. [15] included the following health
states: temporary discontinuers, remission, mild, moder-
ate–severe, surgery, post-surgery remission and post-sur-
gery complications. Archer et al. [16] and Tappenden et al.
[17] divided the model structure into four parts, i.e. on
biological treatment, non-biological treatment, post-sur-
gery, and dead. The first and second parts included the
same states: active UC, response, and remission, while the
third and fourth parts included only one state: post-surgery
(with/without complications) and dead, respectively.
Wilson et al. [14] did not include the response state, but
instead two others were included: mild with a Mayo score
of 3–5 and moderate–severe with a Mayo score of 6–12.
Additionally, six other states were included: remission with
a Mayo score of 0–2, surgery (from moderate–severe state),
post-surgery remission, post-surgery complications, dis-
continue and death.
In the analysis by Xie et al. [18], three strategies were
included: usual care, infliximab 5 mg/kg followed by
adalimumab, and infliximab 5 mg/kg followed by inflix-
imab 10 mg/kg and then adalimumab. The states in the
model were similar to those in other studies, i.e. response,
remission, surgery, complications, and active disease.
We also compared the model structures in analyses
where the decision trees were the chosen methods of
modelling [11–14]; a significant heterogeneity in the
approaches used in the considered analyses was revealed.
The structure of the decision trees and the assumptions
included in the modelling varied among the studies.
Chaudhary and Fan [12] used the decision tree to
compare infliximab, cyclosporine and surgery over a 1-year
time horizon. The following states were included: surgery
or remission after pharmacotherapy, and remission or
complication after surgery.
In another study, infliximab treatment was compared
with standard care, cyclosporine and surgery [13]. The
states included initial remission and early surgery, and
initial remission transitioned to ongoing remission and late
surgery states.
Quite a simple version of the decision tree was used in
the study by Wilson et al. [14] for the evaluation of bio-
logic induction. Patients who responded to therapy during
the induction period and did not discontinue as a result of
adverse effects, remained on maintenance treatment (en-
tered Markov model). Patients who did not respond during
the induction phase, lost response during the maintenance
phase, or discontinued due to adverse events switched to
induction with conventional therapy [14].
No detailed structure of the decision analytical model
was provided in the case of the decision tree used to
compare the cost-effectiveness of the first-line treatment
with adalimumab, infliximab or vedolizumab to induce
mucosal healing [11]. The authors presented only a sim-
plified scheme, without particular states or transitions. The
lack of data on the methods used makes it impossible to
compare the model structure with other analyses.
3.5 Data Sources
The half of analyses included the results of single clinical
trials collected in the review of literature in order to esti-
mate the transition probabilities in the model
[10–12, 15, 19, 22–24]. In other studies, the meta-analyses
and indirect comparisons (network meta-analyses) of the
identified clinical trials were conducted to obtain the
clinical data used as input for simulations
[13, 14, 16–18, 20, 21, 25].
The country databases were a source of information to
estimate the unit costs of drugs and medical services in 13
of 16 identified analyses [10–19, 21, 22, 24]. In only two
studies [20, 23] was the literature search conducted to
obtain the cost data. In study by Essat et al., no information
on cost sources was provided [25].
4 Discussion
We identified 16 economic analyses, mainly cost-utility
analyses, which assessed the cost-effectiveness of biologic
drugs (infliximab, adalimumab, golimumab, and vedolizu-
mab) in the treatment of UC. The assessed interventions
were mainly compared with standard care alone, but
cyclosporine, surgical intervention and other biologics were
also included as comparators in some cases. The highest
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number of economic analyses related to infliximab, and only
three of the analyses included vedolizumab, including one
HTA report. The vast majority of studies used Markov
modelling and only five studies used the decision trees. All
Markov models included response, remission, and surgery
states, but response state was, in some cases, replaced by
mild state. The second-line biologic treatment was rarely
included in the analysis. The structure of decision trees
varied significantly between the studies. The most com-
monly applied time horizon was lifetime (30 years or more),
which was adopted in 44% of analyses (7 of 16), but a 1-year
time horizon was also employed quite often (27% of the
analyses). In our opinion, a lifetime horizon is more valuable
for chronic diseases as the longer period of observation
provide more sophisticated information on consequences of
therapy compared with a 1-year horizon. The QALY was
used as an outcome in 88% of the analyses, while the other
analyses used remission, response and mucosal healing.
Cost-effectiveness studies on new treatments should take
into consideration the impact of the new interventions on
patient productivity and a corresponding economic burden
for the society. Therefore, it should be emphasized that only
two of the economic analyses also carried out the calcula-
tions from a social perspective, and took into account the
impact of treatment on work productivity, which seems quite
unusual because UC, a condition usually diagnosed in
middle-aged patients, generates a significant loss of pro-
ductivity; therefore, indirect costs could even exceed direct
healthcare costs. Both analyses were conducted in Polish
settings [22, 24]. Further studies should be performed to
measure the influence of productivity loss on the cost-ef-
fectiveness of biologic drugs in UC.
The quality of the included analyses was evaluated as
high, based on review of methodologies used and total
score of the CHEERS reporting quality. A majority of
valuable and important information referring to reporting
quality was provided in the reports collected, excluding the
description of national healthcare systems or reimburse-
ment status of assessed intervention, which was quite rarely
presented in the analyses.
According to reimbursement criteria, the accept-
able cost-effectiveness of biologics compared with stan-
dard care alone was revealed in only three studies. The
performed sensitivity analyses demonstrated that the cost-
effectiveness results (ICER/ICUR values) were the most
sensitive to the change of utility weights and clinical
parameters (response/remission rates, transition probabili-
ties). The between-study comparison may suggest that the
longer the time horizon, the lower the ICUR values. This
may result from the fact that UC is a lifelong disease and
its effects revealed during the whole lifespan.
The included analyses were country-specific as they
included the costs of therapies valid for each specified
country. Clinical outcomes can be transferred to other
countries and generalized; however, cost inputs are largely
country-specific, which in turn limits the transferability and
generalizability of the results and conclusions to other
countries. Another issue is the differences in healthcare
systems and reimbursement policies between countries,
and also the methods of inpatient or outpatient care, which
may have a significant influence on the results and final
conclusions of economic evaluations.
We critically reviewed the collected publications but
also discussed the model structures, cost sources, model
assumptions, model validation and key drivers for cost-
effectiveness analyses to provide a substantial contribution
over the existing reviews in the topic.
We limited the final review to studies written in English,
which may be considered as a limitation, as this approach
produced the potential omission of relevant papers. Several
identified analysis were conducted directly by manufacturers
and their results were published in a form of an HTA report.
We did not include the results of manufacturers’ calculations,
which may also be a limitation, but the results of analysis
carried out by HTA agencies were taken into account. Such an
approach was implemented because manufacturers’ analysis,
which are industry-sponsored evaluations, may be biased.
Another limitation is that the quality assessment was not
performed for one analysis [25]. The analysis results were
presented as an ERG assessment and did not include the
structure typical for economic evaluations. The heterogeneity
of model assumptions was the reason why meta-analysis was
not performed for identified studies, which also constitutes a
limitation of this review.
Despite the above limitations, we included the majority
of cost-effectiveness studies currently available, which
enabled us to evaluate the overall quality and identify key
drivers of cost-effectiveness.
This study is the most comprehensive review that incor-
porates economic evaluations referring to UC treatments. It
includes quality assessment with a validated instrument and
in-depth analysis of cost-effectiveness key drivers.
There is a need for studies that will provide evidence for
the effectiveness of long-term treatment of UC and resolve
the uncertainty associated with the key drivers of
efficiency.
5 Conclusions
We identified well-reported economic analyses providing
conclusions on the cost-effectiveness of infliximab, adali-
mumab, golimumab and vedolizumab therapy in UC.
Conclusions based on the performed cost-effectiveness
analyses were not unequivocal. The key drivers identified
in the review were utility weights and clinical inputs.
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